Skip to main content
SpringerLink
Log in

Survival and tumor characteristics of German hereditary breast cancer patients

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Reports from different countries have been inconclusive in attempting to relate the BRCA1 mutation status to the survival of breast cancer patients. The purpose of this study was to investigate overall and disease-free survival for German hereditary breast cancer patients. Data on clinical outcome and data on age at diagnosis of breast cancer, histology, tumor size, lymph node status, histological grade, and laterality of 36 breast cancer patients from 12 families with a BRCA1 mutation and from one family with strong evidence for linkage to BRCA1 were compared with those of 49 hereditary breast cancer patients from 23 families that did not harbor a BRCA1 mutation. Overall and disease-free survival was estimated for both groups. BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04). Also, BRCA1-associated tumors more frequently were of larger size (p = 0.041) and higher grade of malignancy (p = 0.005) than non-BRCA1-associated tumors. Whereas no difference in overall survival was seen, disease-free survival at 10 years differed significantly with 53.3% for BRCA1 mutation carriers and 76% for non- carriers (p = 0.02). However, after stratification for age and in multivariate analysis for mutation status, age, and bilaterality, it was shown that the worse prognosis for BRCA1 mutation carriers disappeared. Our results suggest that the worse prognosis of BRCA1 mutation carriers in terms of disease-free survival may in large part be due to the age of onset of breast cancer in this population. Thus, BRCA1 mutation status does not appear to be an independent prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Casey G: The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol 9: 88–93, 1997

    Google Scholar 

  2. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Häufigkeiten und Trends. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (Hrsg), Saarbücken, 1997

    Google Scholar 

  3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71, 1994

    Google Scholar 

  4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689, 1998

    Google Scholar 

  5. Breast Cancer Information Core: http://www.nhgri.nih.gov/ Intramural_research/Lab_transfer/Bic, 1999

  6. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCAl-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265–271, 1995

    Google Scholar 

  7. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684–1689, 1990

    Google Scholar 

  8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692–695, 1994

    Google Scholar 

  9. Cornelis RS, Vasen HFA, Meijers-Heijboer H, Ford D, van Vliet M, van Tilborg AAG, Cleton FJ, Klijn JGM, Menko FH, Meera Khan P, Cornelisse CJ, Devilee P: Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet 95: 539–544, 1995

    Google Scholar 

  10. Jacquemier J, Eisinger F, Birnbaum D, Sobol H: Histoprognostic grade in BRCA1-associated breast cancer. Lancet 345: 1503, 1995

    Google Scholar 

  11. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent Salomon A, Jacquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56: 471–474, 1996

    Google Scholar 

  12. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77: 697–709, 1996

    Google Scholar 

  13. Sobol H, Stoppa-Lyonnet D, Bressac de Paillerets B, Peyrat JP, Kerangueven F, Janin N, Noguchi T, Eisinger F, Guinebretiere JM, Jacquemier J, Birnbaum D: Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 56: 3216–3219, 1996

    Google Scholar 

  14. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505–1510, 1997

    Google Scholar 

  15. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33: 362–371, 1997

    Google Scholar 

  16. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642–1649, 1998

    Google Scholar 

  17. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG: Survival and tumour characteristics of breastcancer patients with germline mutations of BRCA1. Lancet 351: 316–321, 1998

    Google Scholar 

  18. Porter DE, Cohen BB,WallaceMR, Smyth E, Chetty U, Dixon JM, Steel CM, Carter DC: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81: 1512–1515, 1994

    Google Scholar 

  19. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN: Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3: 2465–2469, 1997

    Google Scholar 

  20. Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA: Survival of patients with breast cancer and BRCA1 mutations. Lancet 351: 1359–1360, 1998

    Google Scholar 

  21. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a populationbased study from southern Sweden. J Clin Oncol 16: 397–404, 1998

    Google Scholar 

  22. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P: Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 91: 259–263, 1999

    Google Scholar 

  23. Hamann U, Brauch H, Garvin AM, Bastert G, Scott RJ: German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene. Gen Chrom Cancer 18: 126–132, 1997

    Google Scholar 

  24. Hamann U, Häner M, Stosiek U, Bastert G, Scott RJ: Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families. J Med Genet 34: 884–888, 1997

    Google Scholar 

  25. Hamann U, Becher H, Zimmermann T, Pella K, Bastert G, Chang-Claude J: German family study on hereditary breastovarian cancer. J Med Genet 33: 633–635, 1996

    Google Scholar 

  26. Chang-Claude J, Becher H, Eby N, Bastert G, Wahrendorf J, Hamann U: Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 123: 272–279, 1997

    Google Scholar 

  27. Cox DR: Regression models and life tables. JR Statist Soc B 34: 187–220, 1972

    Google Scholar 

  28. Brunet J-S, Narod SA, Tonin P, Foulkes WD: BRCA1 mutations and survival in women with ovarian cancer (letter; comment). N Engl J Med 336: 1256, 1997

    Google Scholar 

  29. Rosen PP, Lesser ML, Kinne DW: Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years and older than 75 years. J Surg Oncol 28: 90–96, 1985

    Google Scholar 

  30. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM: Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 8: 591–598, 1990

    Google Scholar 

  31. Vanlemmens L, Hebbar M, Peyrat JP, Bonneterre J: Age as a prognostic factor in breast cancer. Anticancer Res 18: 1891–1896, 1998

    Google Scholar 

  32. Feldman AL, Welch JP: Long-term outcome in women less than 30 years of age with breast cancer. J Surg Oncol 68: 193–198, 1998

    Google Scholar 

  33. Marcus JN, Watson P, Page DL, Lynch HT: Pathology and heredity of breast cancer in younger women. Monogr Natl Cancer Inst 16: 23–34, 1994

    Google Scholar 

  34. Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 30: 23–33, 1994

    Google Scholar 

  35. Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials? Monogr Natl Cancer Inst 16: 35–42, 1994

    Google Scholar 

  36. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462–469, 1998

    Google Scholar 

  37. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D: Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 352: 541, 1998

    Google Scholar 

  38. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 997–1003, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Genome Analysis, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    Ute Hamann

  2. Department of Pathology, University of Heidelberg, Heidelberg, Germany

    Hans-Peter Sinn

Authors
  1. Ute Hamann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Peter Sinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamann, U., Sinn, HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 59, 185–192 (2000). https://doi.org/10.1023/A:1006350518190

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006350518190

Search

Navigation